Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With (N)STEMI or Unstable Angina

NCT ID: NCT05600088

Last Updated: 2025-01-30

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-05-18
• Study Completion Date: 2026-07-31

Brief Summary

The POLARSTAR study is an early safety and feasibility study to evaluate the performance and safety of the CryoTherapy System (CTS) for the treatment of coronary plaque lesions that are not obstructing blood flow but are at high-risk of rupture which would cause a major heart attack. The CTS is used to apply local freezing of the lesion using a balloon catheter, controlled by a console that regulates in- and outflow of a cooling agent into the catheter. The treatment is expected to stabilize the lesion, diminishing the risk of rupture. The study will enrol subjects with acute coronary disease who have suitable coronary lesions. Subjects will be followed for 1 year after the CTS treatment. Baseline identification of lesions will be done using Coronary CT-angiography (CCTA), which will be repeated at 3 and 9 months after procedure.

Detailed Description

The POLARSTAR study is an early feasibility study to evaluate the safety and performance of the CryoTherapy System (CTS) medical device, consisting of a console and a balloon catheter. The CTS is designed to deliver local cryo-energy to vulnerable plaque lesions in the coronary arteries, aiming to stabilize the plaque to reduce the risk of rupture and subsequent cardiac events. The study will enrol up to 10 subjects with NSTEMI or unstable angina, who underwent successful Percutaneous Coronary Intervention (PCI) of their culprit coronary lesion, and who were identified to have presence of at least 1 non-culprit suitable plaque lesion at high-risk of rupture. After providing informed consent the subjects will undergo a Coronary CT-angiography (CCTA) to confirm suitability of the coronary plaque lesion. A single high-risk plaque lesion will be treated by the investigators, with Intra-vascular Ultrasound (IVUS) imaging prior to and after CTS treatment. Subjects will be followed clinically for up to one year after the CTS treatment, and will have follow-up CCTA assessments at 3 and 9 months post-procedure. Primary endpoint will be Major cardiac events rate at 3 months post procedure.

Conditions

Coronary Artery Disease; Coronary Syndrome; Cryotherapy Effect; Myocardial Infarction; Myocardial Disease; Atherosclerosis, Coronary

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DEVICE_FEASIBILITY
• Blinding Strategy: NONE

Study Groups

CTS Treatment Arm

active cryotherapy of a single suitable high-risk coronary plaque lesion with CTS device

Group Type: EXPERIMENTAL

CryoTherapy System (CTS)

Intervention Type: DEVICE

local cryotherapy of coronary high-risk plaque lesions using the CTS consisting of a semi-compliant balloon and a console controlling the temperature of cryotherapy

Interventions

CryoTherapy System (CTS)

local cryotherapy of coronary high-risk plaque lesions using the CTS consisting of a semi-compliant balloon and a console controlling the temperature of cryotherapy

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Subject is at least 18 years old.

2. Subject has acute cardiac pain/angina consistent with acute coronary syndrome eligible for coronary angiography meeting one of the following criteria:

1. (Non-)ST-segment elevation myocardial infarction ((N)STEMI) with rise/fall of cardiac enzymes (troponin I or T) with at least one value above the 99th percentile of the upper reference limit requiring PCI within 72 hours from diagnosis

2. Unstable angina

3. Successful PCI (defined as diameter stenosis less than 30% and TIMI 3 flow on final angiography without procedural complication) of the culprit lesion.

4. Subject has at least one high-risk plaque meeting the criteria below:

1. Located in a non-culprit vessel,

2. High-risk plaque lesion on CCTA and at least one of the following features:

1. Presence of low-attenuation plaque (HU<50) and/or

2. Positive remodelling (remodelling index >1.1) and/or

3. Napkin ring sign and/or

4. Plaque burden ≥70%

3. Lesion length ≤ 20 mm.

4. Diameter stenosis on invasive angiography between 30% and 70% on coronary angiogram or negative physiology assessment (FFR>0.80 or non-hyperemic pressure ratios (NHPR) >0.89).

5. Reference vessel diameter (RVD) < 3.75 mm and > 2.00 mm in diameter

6. Investigator considers that lesions are accessible.

7. If more than two suitable lesions available, investigator will select the most appropriate lesion for cryotherapy treatment.

5. Subject is able to provide consent and has signed and dated the informed consent form.

Exclusion Criteria

1. Subject is hemodynamically unstable (cardiogenic shock, hypotension needing inotropes, hypoxia needing intubation, refractory ventricular arrhythmias, and IABP).

2. Subject has ongoing ST-segment elevation myocardial infarction.

3. Subject had a procedural complication during the Acute coronary syndrome (ACS) PCI procedure.

4. Subject has history of Coronary Artery Bypass Graft (CABG) or planned CABG within 12 months after the index procedure.

5. Subject has known reduced Left Ventricular Ejection Fraction < 30%.

6. Subject has known severe valvular heart disease.

7. Subject has known severe renal insufficiency (eGFR <30 ml/min/1.72 m2).

8. Subject has any life-threatening conditions or medical comorbidity resulting in life expectancy < 12 months.

9. Subject is currently participating in another clinical investigation that has not yet reached its primary endpoint.

10. Subject is pregnant or lactating, or NOT surgically sterile (tubal ligation or hysterectomy) or NOT postmenopausal for at least 6 months or is a female with childbearing potential without effective contraception (pill, patch, ring, diaphragm, implant and intrauterine device).

1. Visible distal embolization/no-reflow following culprit lesions PCI.

2. Left main coronary artery disease (visual diameter stenosis > 50%).

3. Stent thrombosis/restenosis as a culprit lesion.

4. CTS lesion involving a bifurcation (defined as lesions involving side branches >2.0 mm).

5. Angiographic or CCTA evidence of severe calcification and/or marked tortuosity of the index vessel and/or lesion.

6. Thrombotic lesions

7. Ostial lesions

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

CoreAalst BV

INDUSTRY

Sponsor Role: collaborator

Cryotherapeutics SA

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Irakli Gogorishvili, MD

Role: PRINCIPAL_INVESTIGATOR

Israeli_Georgian research Clinic Helsicore, Tbilisi, Georgia

Locations

Israeli-Georgian Research Clinic Helsicore

Tbilisi, , Georgia

Site Status: RECRUITING

Tbilisi Heart Center

Tbilisi, , Georgia

Site Status: RECRUITING

Hospital of Lithuanian University of health sciences Kauno Klinikos

Kaunas, , Lithuania

Site Status: RECRUITING

Klaipèda University Hospital

Klaipèda, , Lithuania

Site Status: RECRUITING

Vilnius University Hospital Santaros Klinikos

Vilnius, , Lithuania

Site Status: RECRUITING

Countries

Georgia; Lithuania

Central Contacts

Danny Detiege, RN

Role: CONTACT

dde@cryotherapeutics.com

+32467024773

Facility Contacts

Irakli Gogorishvili, MD

Role: primary

gogorishvili@gmail.com

+995 32 243 33 43

Archil Chukhrukidze, MD

Role: primary

achidoc@gmail.com

+995 32 250 81 06

Ramunas Unikas, MD

Role: primary

ramunas.unikas@kaunoklinikos.lt

+370 377 03247

Andrej Pileckij, MD

Role: primary

a.pileckij@gmail.com

+370 46 396502

Giedrius Davidavicius, MD

Role: primary

giedrius.davidavicius@santa.lt

+370 655 05602

Other Identifiers

CT-CD-P03-1

Identifier Type: -

Identifier Source: org_study_id